Differential effects of various genetic mouse models of the mechanistic target of rapamycin complex I inhibition on heart failure.
Animals
Blotting, Western
DNA
/ genetics
Disease Models, Animal
Gene Expression Regulation
Heart Failure
/ drug therapy
Immunosuppressive Agents
/ pharmacology
Male
Mechanistic Target of Rapamycin Complex 1
/ antagonists & inhibitors
Mice
Mice, Transgenic
Proteome
Signal Transduction
Sirolimus
/ pharmacology
Aging
Heart failure
Nutrient signaling
Proteomics
mTOR
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
18
09
2019
accepted:
04
10
2019
pubmed:
28
10
2019
medline:
10
7
2020
entrez:
26
10
2019
Statut:
ppublish
Résumé
Inhibition of mammalian target of rapamycin complex I (mTORC1) by rapamycin improves cardiac function in both aging and heart failure. While the protective mechanisms are not fully understood in mammals, they are presumably mediated through metabolic regulation and suppression of protein translation by reduced phosphorylation of 4EBP1, a target of mTORC1. Using transverse aortic constriction (TAC) and Gαq overexpression-induced heart failure models, we examined the effect of cardiac-specific heterozygous deletion (het) of Raptor, a component of mTORC1, and cardiac-specific transgenic overexpression of wild type or phosphorylation site mutant 4EBP1. In wild-type mice with TAC-induced heart failure, quantitative shotgun proteomics revealed decreased abundance of proteins of mitochondrial metabolism and increased abundance of proteins in oxidative stress response, ubiquitin, and other pathways. The Raptor het ameliorated both TAC- and Gαq overexpression-induced heart failure and the associated proteomic remodeling, especially those pathways involved in mitochondrial function, citric acid cycle, and ubiquitination. In contrast, transgenic overexpression of either wild type or mutant 4EBP1 aggravated TAC and Gαq, consistent with reduced adaptive hypertrophy by suppression of protein translation, in parallel with adverse remodeling of left ventricular proteomes. Partial mTORC1 inhibition by Raptor heterozygous deletion ameliorates heart failure and is associated with better preservation of the mitochondrial proteome; however, this effect does not appear to be mediated through suppression of protein translation by increased 4EBP1. Increased activity of 4EBP1 reduced adaptive hypertrophy and aggravated heart failure, suggesting that protein translation is essential for adaptive hypertrophy in pressure overload.
Identifiants
pubmed: 31650481
doi: 10.1007/s11357-019-00119-6
pii: 10.1007/s11357-019-00119-6
pmc: PMC6925086
doi:
Substances chimiques
Immunosuppressive Agents
0
Proteome
0
DNA
9007-49-2
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
847-860Subventions
Organisme : NIA NIH HHS
ID : R01 AG033082
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL101186
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038550
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG013280
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL145138
Pays : United States
Références
Cell. 2009 Oct 2;139(1):149-60
pubmed: 19804760
Mol Cell Biol. 2004 Jul;24(14):6231-40
pubmed: 15226426
Nature. 2009 Jul 16;460(7253):392-5
pubmed: 19587680
Circulation. 2009 Jun 2;119(21):2789-97
pubmed: 19451351
J Hypertens. 2006 Aug;24(8):1663-70
pubmed: 16877971
J Clin Invest. 2013 Mar;123(3):980-9
pubmed: 23454761
Cell Metab. 2013 Mar 5;17(3):456-62
pubmed: 23473038
Science. 2009 Oct 2;326(5949):140-4
pubmed: 19797661
Science. 2012 Mar 30;335(6076):1638-43
pubmed: 22461615
Physiol Genomics. 2004 Feb 13;16(3):349-60
pubmed: 14679301
Nature. 2010 Mar 25;464(7288):504-12
pubmed: 20336132
Circ Heart Fail. 2013 Sep 1;6(5):1067-76
pubmed: 23935006
Cardiovasc Res. 2012 Jan 1;93(1):79-88
pubmed: 22012956
Cardiovasc Res. 2010 Nov 1;88(2):267-76
pubmed: 20797984
Aging Cell. 2009 Sep;8(5):542-52
pubmed: 19594484
Mol Cell. 2010 Oct 22;40(2):310-22
pubmed: 20965424
J Gerontol A Biol Sci Med Sci. 2011 Feb;66(2):191-201
pubmed: 20974732
Aging Cell. 2014 Jun;13(3):529-39
pubmed: 24612461
J Mol Cell Cardiol. 2012 May;52(5):1066-73
pubmed: 22314372
J Gerontol A Biol Sci Med Sci. 1997 Nov;52(6):B285-90
pubmed: 9402929
Circ Res. 1995 Jan;76(1):1-15
pubmed: 8001266
J Clin Invest. 2015 Aug 3;125(8):2952-64
pubmed: 26121750
Circulation. 2011 Mar 15;123(10):1073-82
pubmed: 21357822
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Cell. 2008 Apr 18;133(2):292-302
pubmed: 18423200
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
J Clin Invest. 2010 Aug;120(8):2805-16
pubmed: 20644257
Circulation. 2001 Oct 2;104(14):1664-9
pubmed: 11581146
J Clin Invest. 2008 Jan;118(1):124-32
pubmed: 18079970
Genome Biol. 2004;5(10):R80
pubmed: 15461798
J Mol Cell Cardiol. 2011 Jan;50(1):117-27
pubmed: 20977912
Mol Cell Biol. 2004 Aug;24(15):6710-8
pubmed: 15254238
Circulation. 2003 Apr 1;107(12):1664-70
pubmed: 12668503
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8121-6
pubmed: 9223325
Nat Commun. 2019 Jul 19;10(1):3194
pubmed: 31324799
J Am Coll Cardiol. 2011 Jun 28;58(1):73-82
pubmed: 21620606
Mol Cell Biol. 2004 Nov;24(21):9508-16
pubmed: 15485918
Circ Res. 2011 Apr 1;108(7):837-46
pubmed: 21311045
Mol Cell Biol. 2002 Apr;22(8):2853-61
pubmed: 11909977
Circulation. 2004 Jun 22;109(24):3050-5
pubmed: 15184287